References
- Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39:1990–2005.
- Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 2009;69:271–8.
- Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncol 2007;46:592–601.
- Pentheroudakis G, Greco FA, Pavlidis N. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A ystematic literature review. Cancer Treat Rev 2009;35:221–7.
- Schuette K, Folprecht G, Kretzschmar A, Link H, Koehne CH, Gruenwald V, . Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary. Onkologie 2009;32:162–6.
- Culine S, Ychou M, Fabbro M, Romieu G, Cupissol D. 5-fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site. Anticancer Res 2001;21:1455–7.
- Hainsworth JD, Burris HA, III, Calvert SW, Willcutt NT, Scullin DC, Jr., Bramham J, . Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: A phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest 2001;19:335–9.
- Hainsworth JD, Spigel DR, Raefsky EL, Kuzur ME, Yost K, Kommor M, . Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: A Minnie Pearl Cancer Research Network Phase II trial. Cancer 2005;104:1992–7.
- Pouessel D, Culine S, Becht C, Romieu G, Fabbro M, Ychou M, . Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site. Anticancer Res 2003;23:2801–4.
- Briasoulis E, Pavlidis N, Felip E. Cancers of unknown primary site: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl 4):154–5.
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16.
- Møller A, Pedersen K, Gothelf A, Daugaard G. Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study. Acta Oncol 2010;49:423–30.
- Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, . Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002;20:4679–83.
- Ponce LJ, Segura HA, Diaz BR, Gimenez OA, Aparisi AF, Fleitas KT, . Carcinoma of unknown primary site: Development in a single institution of a prognostic model based on clinical and serum variables. Clin Transl Oncol 2007;9:452–8.
- Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: The Minnie Pearl Cancer Research Network. J Clin Oncol 2007;25:1747–52.